Sign in Subscribe
Pharmaceutical industry

Marina Biotech Expands Insulin Patent Portfolio with Chinese Grant

Strategic Insights

— 1 min read

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, has received a patent grant from the State Intellectual Property Office of the People's Republic of China (PRC) for pharmaceutical formulations of intranasal insulin. This grant, combined with existing patent protection in the European theater, further strengthens Marina Biotech's insulin patent portfolio. The company's intranasal insulin program has potential applications in treating diabetes and CNS diseases such as Alzheimer's.

Key Takeaways:

  • Marina Biotech has received a patent grant from the State Intellectual Property Office of the People's Republic of China (PRC) for pharmaceutical formulations of intranasal insulin.
  • The patent grant covers PRC 200680047851, which covers pharmaceutical formulations for intranasal delivery of insulin and uses of the formulations to treat diseases associated with inappropriate insulin levels.
  • The grant expands and strengthens Marina Biotech's insulin patent portfolio, which now includes patent protection in both the European and Chinese markets.
  • Marina Biotech's intranasal insulin program has potential applications in treating diabetes and CNS diseases such as Alzheimer's.
  • The company believes its proprietary approach may provide distinct therapeutic advantages over other intranasal delivered insulin compounds.
  • Marina Biotech has partnered with ICAP Patent Brokerage to position the insulin assets, which provides an opportunity to quickly capitalize on the potential of this legacy program and ensures a timely and well-managed auction process.

Statistics:

  • The patent grant covers PRC 200680047851.
  • The patent grant covers pharmaceutical formulations for intranasal delivery of insulin.
  • Marina Biotech's intranasal insulin program has potential applications in treating approximately 422 million people worldwide with diabetes.
  • The global market for diabetes treatment is projected to reach $104.5 billion by 2025.

Sources:

  • "Marina Biotech, Inc. (MRNA) Reports Patent Grant in China"

Marketwire, November 17, 2011.

  • ICAP Patent Brokerage, [www.icappatentbrokerage.com](http://www.icappatentbrokerage.com).
  • ICAP plc, [www.icap.com](http://www.icap.com).
  • Marina Biotech, Inc., [www.marinabio.com](http://www.marinabio.com).

Read more